Deregulation on joint, commissioned bioequivalence testing stirs debate

Published: 2010-07-12 07:00:00
Updated: 2010-07-12 07:00:00
The government’s plan to deregulate the joint, commissioned bioequivalence testing has stirred up concerns among drug companies.

They fear that the new plan could not only slash their profits amid entry of too many players, but push many marginal companies out of business. Many small companies...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.